account_id none on file
legal_name Kyverna Therapeutics, Inc.
ticker KYTX
cik 1994702
domain kyvernatx.com
linkedin_company_url https://www.linkedin.com/company/kyverna/
entry_point_account_id none on file
name Kyverna Therapeutics Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 9 executives 3 family 0
why_nownone on file
callsnone on file
filings
We expect to experience pricing pressures in connection with the sale of all of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.
filing / Aug 11, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.
filing / Aug 11, 2026 / receipt
On February 27, 2026, we entered into a lease amendment to reduce total office and lab space and added new office space in the same building commencing on July 2, 2026.
filing / Aug 11, 2026 / receipt
If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our research and development costs.
filing / Aug 11, 2026 / receipt
government implemented substantial layoffs and workforce reductions in connection with the federal government shutdown, which resulted in the suspension or delay of various government-funded programs.
filing / Aug 11, 2026 / receipt
We expect to experience pricing pressures in connection with the sale of all of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.
filing / May 12, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.
filing / May 12, 2026 / receipt
If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our research and development costs.
filing / May 12, 2026 / receipt
government implemented substantial layoffs and workforce reductions in connection with the federal government shutdown, which resulted in the suspension or delay of various government-funded programs.
filing / May 12, 2026 / receipt
executives
| Gregory Martini | Chief Financial Officer | - | receipt |
| Marc Grasso | Chief Financial Officer | - | receipt |
| Warner Biddle | Chief Executive Officer | - | receipt |
familynone on file
upcoming
| 2026-11-11 | earnings call | scheduled | ir |
changes
| 2026-05-18 | Chief Financial Officer, appointed | sec_8k |
| 2025-06-30 | Chief Financial Officer, appointed | sec_8k |
| 2024-09-16 | Chief Executive Officer, appointed | sec_8k |
mcp_package_hint
slug kyverna-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$